News Sentiment

MLTX sentiment intelligence

MoonLake Immunotherapeutics news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 20.36 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+7.4% over one week, +8.9% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Jerucon plans 150,000-share MLTX sale in Form 144 (Nasdaq: MLTX)

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction 7.4% Price confirming higher
Trend fit Trend active 8.9% over four weeks
Fair value -49.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 40
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 17
Market source 10
TradingView 5
simplywall.st 5
Stocktwits 3
The National Law Review 2
MT Newswires 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 13
Regulatory and legal 3
Guidance 1
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
Stock Titan Direct company coverage

MoonLake seeks $200M to fund sonelokimab work

MoonLake Immunotherapeutics has priced an upsized underwritten public offering to raise approximately $200 million in gross proceeds. The funds, combined with existing cash, are intended to finance the research, development, and potential commercialization of sonelokimab, a novel

Tone
Negative 40/100
Event
Balance sheet
Published
24 Jun 2026 07:11
Source
Stock Titan
MSN Direct company coverage

MoonLake Immunotherapeutics announces $150M public offering

MoonLake Immunotherapeutics has announced a public offering aimed at raising $150 million. The company is involved in the biotechnology sector, focusing on immunotherapeutics. This offering is likely intended to fund ongoing research, clinical trials, or general corporate purpose

Tone
Positive 59/100
Event
Market update
Published
24 Jun 2026 07:10
Source
MSN
GlobeNewswire Direct company coverage

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MoonLake Immunotherapeutics announced the pricing of an upsized public offering expected to raise approximately $200 million. The offering includes 9,000,000 Class A ordinary shares at $20.00 each and pre-funded warrants for an additional 1,000,000 Class A ordinary shares. Procee

Tone
Positive 65/100
Event
Market update
Published
24 Jun 2026 03:11
Source
GlobeNewswire
Quiver Quantitative Direct company coverage

MoonLake Immunotherapeutics Prices $200 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

MoonLake Immunotherapeutics announced the pricing of a public offering of 9,000,000 Class A ordinary shares at $20.00 each, and pre-funded warrants for an additional 1,000,000 shares at $19.9999 each, aiming to raise approximately $200 million. The proceeds will fund the research

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 03:10
Source
Quiver Quantitative
Stock Titan Direct company coverage

MoonLake Immunotherapeutics (MLTX) CFO sells 39,120 shares in open-market trade

MoonLake Immunotherapeutics' CFO, Matthias Bodenstedt, sold 39,120 Class A ordinary shares on June 22, 2026, at a weighted average price of $22.04 per share. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, represents a small port

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 19:40
Source
Stock Titan
Moomoo Direct company coverage

MoonLake Immunotherapeutics | 424B5: Prospectus

MoonLake Immunotherapeutics has announced a public offering of Class A Ordinary Shares and pre-funded warrants aiming for gross proceeds of $150 million. The offering price for Class A Ordinary Shares is $22.16, matching the last Nasdaq Capital Market sale price. The company plan

Tone
Positive 61/100
Event
Market update
Published
23 Jun 2026 01:40
Source
Moomoo
Stock Titan Direct company coverage

MoonLake Immunotherapeutics (NASDAQ: MLTX) seeks $150M via offering

MoonLake Immunotherapeutics is conducting a public offering to raise $150 million through the sale of Class A Ordinary Shares and pre-funded warrants. The company intends to use the net proceeds, along with existing funds, to advance the research, development, and potential comme

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 22:11
Source
Stock Titan
Stock Titan Direct company coverage

MoonLake seeks $150M in stock sale to fund sonelokimab work

MoonLake Immunotherapeutics (NASDAQ: MLTX) announced a proposed public offering of $150 million in Class A ordinary shares and pre-funded warrants. The proceeds are intended to fund the development and potential commercialization of sonelokimab, as well as for general corporate p

Tone
Negative 38/100
Event
Market update
Published
22 Jun 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

MoonLake Immunotherapeutics (MLTX) director receives 22,195 stock options grant

MoonLake Immunotherapeutics director Catherine Moukheibir was granted 22,195 options to purchase Class A ordinary shares. The options have an exercise price of $19.19 per share and expire on June 17, 2036. These options will vest in full on the earlier of June 17, 2027, or the co

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

MoonLake Immunotherapeutics (MLTX) director granted options on 22,195 shares

MoonLake Immunotherapeutics director Andrew John Phillips has been granted stock options for 22,195 Class A ordinary shares, with an exercise price of $19.19 per share. These options will vest in full either on June 17, 2027, or at the company's next annual general meeting, conti

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 23:09
Source
Stock Titan